logo
Genetic testing IDs some at higher risk for colorectal cancer

Genetic testing IDs some at higher risk for colorectal cancer

Yahoo28-03-2025

DUPAGE COUNTY, Ill. (WGN) — It's a quiet day in Wheaton, and Jessica Wozniak is in her kitchen, making a cup of tea.
The mother of a preschooler is taking advantage of some time to relax, read, and rest. The 36-year-old needs to save the strength she has for what's coming the next day: chemotherapy at Duly Health's cancer infusion center in Hinsdale.
'Chemo's miserable,' she said. 'It's really, really not fun.'
With her husband Patrick by her side, she's undergoing her eighth cycle of chemotherapy. Her hands and feet are covered in 'cold gloves and socks' to reduce two of chemo's most uncomfortable side-effects: cold sensitivity and neuropathy.
Her health ordeal started about one year ago when she came down with norovirus, an intense flu-like sickness that usually passes through the body within about 48-hours. But her abdominal pain lingered much longer.
'About a month after that, I was still having intermittent symptoms stomach pain,' Wozniak said. 'Diarrhea. Something was unsettled. But it seemed like I couldn't have a virus for that long.'
At first, doctors suspected that she had developed an ovarian cyst. 'I still was just feeling – in the morning – a cramping pain,' she said. 'Doubling over. I thought this was just not normal. So, I went to my primary care doctor, and she said this doesn't sound like it's only a cyst, let's send you for a CT. Sure enough, they saw some inflammation in my colon.'
Doctors ordered a colonoscopy and found she had two masses in her colon.
It was cancer.
'I realized right away that everything was going to be different, especially when I had another CT that showed some lesions on my liver, and again I was told, 'oh these could just be fluid filled cysts, nothing,'' she said. 'But it was this kind of intuition that this is not good, and sure enough those came back as cancerous, too.'
The cancer had advanced to stage four, meaning it had spread to other organs. 'Everything you hear about stage 4, you think this is not, this is going to be terminal for me, what am I going to do, I'm 35, I have a three-year-old, so it was pretty devastating and dark for those first few months,' she said.
According to the American Cancer Society, colorectal cancer is the leading cause of cancer death in men younger than 50, and the number two cause of cancer death among women under 50.
'There were a lot of moments where I just cried,' Wozniak said. 'I sat there crying and thinking, 'why is this happening to me?''
Wozniak is one of nearly 20,000 people younger than 50 who were diagnosed with colorectal cancer last year – a dramatic increase and a medical mystery.
'A lot of the media about it is in terms of, like, the environment, what people are eating, lifestyle choices and whatnot,' said Patrick Woulfe, Wozniak's husband. 'I think in Jessica's case that's not necessarily true because hers is due to a genetic condition.'
In Wozniak's case, the cause is clear. She has Lynch Syndrome, an inherited genetic condition associated with an increased risk for colon cancer.
'When I received the genetic test results that almost gave me some piece of mind because I thought, I was blaming myself a lot,' she said. 'Did I eat something that wasn't right? Did I do something to my body? What caused this? The genetic tests made me feel like, in a way, this was inevitable.'
Outside of genetic testing, colorectal cancers can be detected with colonoscopies.
In 2021 the U.S. Preventive Services Task Force lowered the recommended age of screenings from 50 to 45. It's still not young enough to catch many of the new cases.
'I would have rather had a million colonoscopies than deal with this,' Wozniak said. 'A colonoscopy is nothing compared to going through colon cancer.'
Wozniak is sifting through a pile of medical bills, and insurance information, wearing bracelets with the words 'fearless,' 'tough kid,' and her daughter's name. She said she wants to tell her story for her daughter and for everyone else who may have a chance to get screened before they get sick.
'I wish I would have known much sooner, so I could have been screened sooner and caught this sooner,' she said.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

South Side boxing event aims to find cure for children's brain tumor
South Side boxing event aims to find cure for children's brain tumor

Yahoo

time18 minutes ago

  • Yahoo

South Side boxing event aims to find cure for children's brain tumor

CHICAGO (WGN) — It's just about time to get ready to rumble for a good cause on the city's South Side. Dan Letz is the owner and operator of Letz Box Chicago—a pugilistic palace in Mount Greenwood. For the last several months, he's been training a good-hearted, fleet-footed field of warriors who are fighting to help find a cure for Diffuse Intrinsic Pontine Glioma (DIPG), which is a brain tumor that can develop in the brainstem. 'It's horrific. It affects mainly children,' Katie Gaskin said. 'It's a tumor that grows within the brain stem, specifically in the ponds, and when a child is diagnosed with this, right now, they're really only given radiation as a treatment option and usually eight to 12 months to live.' Gaskin's son, Anthony, was 7 years old when he died from DIPG, just 19 months after his diagnosis. In memory of Anthony, who Gaskin described as an old soul who loved the Chicago Cubs, she started the Anthony's Avengers DIPG Foundation. Letz and Gaskin have partnered to host an event on Friday, June 13 at Saint Rita of Cascia High School in benefit of Anthony's Avengers and their mission to find a cure. Starting at 7 p.m., the St. Rita Mustang's football field will be transformed into a boxing ring under the Friday night lights of a different sort. 19-year-old Julian 'J-Dog' Guzman, a University of Illinois-Chicago student studying architecture, is one of those boxers training under Letz who aim to lend a hand, while also landing a punch. 'I'm feeling good. I'm ready to put on a performance,' Guzman said. 'I've been training hard. I'm ready to put on in the ring.' All money raised by Anthony's Avengers during the event will go to DIPG cure research. For more information on Anthony's Avengers and the fight to cure DIPG, visit the organization's website: Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

‘Marbles in the rear ends of cats': WGN fact checks Hegseth's claim
‘Marbles in the rear ends of cats': WGN fact checks Hegseth's claim

Yahoo

timean hour ago

  • Yahoo

‘Marbles in the rear ends of cats': WGN fact checks Hegseth's claim

Defense Secretary Pete Hegseth's testimony before the Senate Ways and Means Committee on Wednesday took an unexpected twist when he mentioned cats, marbles, and medical research. Hegseth was facing questions from Sen. Dick Durbin (D-Illinois) about cuts to the Defense Department's medical research budget when he made a startling claim: 'We're talking about some stuff I shouldn't, shouldn't say in public, you know, marbles in the rear ends of cats, tens of millions of dollars,' Hegseth told Illinois' senior U.S. senator. Hegseth referred to the research as a 'boondoggle.' WGN Investigates: Investigating public corruption, crime & fraud Durbin immediately fired back, asking whether Hegseth's claim was similar to unproven tales told by President Donald Trump and his DOGE team about people hundreds of years old still receiving Social Security checks in their name. The research Hegseth appears to be referencing was money awarded in 2020, during President Trump's first term, to reimburse the University of Pittsburgh $10M for research to 'develop revolutionary new treatment approaches for spinal cord injuries.' The contract award is available on the Department of Defense website. Hegseth's claim about marbles being inserted into the rear ends of cats is correct, but lacks all context. Soldiers – or anyone else – who suffer severe spinal cord injuries can lose control of their bowels. The study used anesthetized cats as test subjects to study the impact of a new procedure to restore functionality in the sphincter and rectum. The marbles were meant to simulate defecation and determine whether a procedure restored control in test subjects. The results were encouraging, according to the American Journal of Physiology. '[The] study indicates the possibility to develop a novel…device to restore defecation function after spinal cord injury using a minimally invasive surgical approach.' Read more: Latest Chicago news and headlines Durbin said Hegseth's proposed budget cuts two-thirds of funding for the Defense Department's medical research. Hegseth countered that his team was targeting 'waste, fraud, and abuse' and would not cut funding for programs that benefit members of the military. He previously announced $5 billion in cuts across the entire Department of Defense. 'The Defense Department has been a place where organizations, entities, and companies know they can get money almost unchecked, whether or not it actually applies to things that happen on the battlefield,' Hegseth told Durbin. 'That's just that's what we worked very hard to find in ways that other secretaries have not.' After the hearing, a spokesperson for Sen. Durbin told WGN: 'While Secretary Hegseth attempted to distract from the larger issue with his comment about marbles and cats, here are just a few examples of DoD research contracts that have been canceled or frozen under this Administration: new breast cancer and prostate cancer therapies, which would help afflicted service members; improved protective gear to defend soldiers against projectiles and chemical threats; advanced materials for more durable and lightweight aircraft parts—and the list goes on. Do these sound like 'boondoggles' to you?' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Testicular Cancer Epidemiology Review 2014-2024 and Forecast 2025-2034: US, UK, France, Italy, Spain, Germany, Japan, and India
Testicular Cancer Epidemiology Review 2014-2024 and Forecast 2025-2034: US, UK, France, Italy, Spain, Germany, Japan, and India

Yahoo

time16 hours ago

  • Yahoo

Testicular Cancer Epidemiology Review 2014-2024 and Forecast 2025-2034: US, UK, France, Italy, Spain, Germany, Japan, and India

In 2025, the American Cancer Society projects 9,729 new testicular cancer cases in the USA, with nearly 600 deaths. Most diagnoses occur at age 33. This report offers comprehensive analyses, treatment insights, and trends across eight key markets, including the US, UK, and Japan. Dublin, June 11, 2025 (GLOBE NEWSWIRE) -- The "Testicular Cancer Epidemiology Forecast 2025-2034" report has been added to to the American Cancer Society, approximately 9,729 new cases of testicular cancer are expected to be identified in The United States in 2025. Additionally, the disease is projected to cause nearly 600 deaths in the same year. The typical age at which individuals are diagnosed with testicular cancer is around 33 Cancer Epidemiology Forecast Report CoverageThe report delivers a comprehensive analysis of the condition's prevalence and associated demographic factors. It projects future incidence and prevalence trends across diverse population groups, considering key variables such as age, gender, and testicular cancer type. The report highlights changes in prevalence over time and offers data-driven forecasts based on influencing factors. Additionally, it provides an in-depth overview of the disease, along with historical and projected epidemiological data for eight key markets:The United States, United Kingdom, France, Italy, Spain, Germany, Japan, and OverviewThe epidemiology section on testicular cancer provides detailed insights into the patient population from historical data to present-day figures, along with forecasts across the eight major markets. The Research analyses multiple studies to outline both existing and anticipated trends. The report highlights diagnosed case numbers, segmented by factors such as age groups and patient demographics. According to the American Cancer Society, approximately 1 in 250 males will be diagnosed with testicular cancer in their lifetime. Research indicates the average age of diagnosis is 33, with 8% of cases found in men over 55 and 6% in children and teenagers. Cancer Research UK reported around 2,376 testicular cancer cases between 2017 and 2019 in the UK, with roughly 65 deaths. Among racial groups, white men in The United States show the highest incidence of the disease. Treatment Overview Treatment for testicular cancer typically involves a multidisciplinary approach, including surgery, chemotherapy, radiotherapy, and active surveillance depending on the cancer type and stage. The majority of patients are diagnosed early, leading to high survival rates. Seminomas and non-seminomas, the two main types of testicular cancer, respond well to treatment. Physicians determine treatment based on tumour markers, imaging results, and pathology. Advancements in targeted therapies and fertility preservation methods are improving outcomes and quality of life. Below are key treatment options commonly used for testicular cancer:1. OrchiectomyOrchiectomy is the primary surgical treatment for testicular cancer. It involves the removal of one or both testicles through an incision in the groin. This procedure is often the first step after diagnosis and provides tissue for further pathological analysis. Orchiectomy helps prevent cancer spread and is usually followed by additional therapies depending on the tumor stage and type. The surgery is typically straightforward and recovery time is short. Fertility and hormone levels can be affected, so patients may consider sperm banking and testosterone monitoring post-surgery.2. ChemotherapyChemotherapy uses powerful drugs to eliminate cancer cells, particularly in advanced or metastatic testicular cancer. It is especially effective for non-seminomatous germ cell tumors. Commonly used regimens include BEP (Bleomycin, Etoposide, and Cisplatin), usually administered over several cycles. Chemotherapy is often recommended after orchiectomy if cancer has spread to lymph nodes or distant organs. While highly effective, it can cause temporary side effects such as nausea, fatigue, hair loss, and increased infection risk. Long-term effects like infertility or cardiovascular issues are monitored in survivorship care plans.3. RadiotherapyRadiotherapy is most commonly used to treat seminomas, which are highly sensitive to radiation. It involves directing targeted radiation beams at lymph nodes, usually in the abdominal or pelvic region, to destroy residual cancer cells. This treatment is generally used after surgery if there's a high risk of recurrence. Radiotherapy is less frequently used for non-seminomas due to lower effectiveness. Side effects may include fatigue, skin irritation, and digestive issues. Advances in imaging and technology have improved the precision of radiation delivery, minimizing damage to healthy tissues.4. Retroperitoneal Lymph Node Dissection (RPLND)RPLND is a complex surgical procedure performed to remove lymph nodes in the abdomen where testicular cancer may spread, especially in cases involving non-seminomatous germ cell tumors. This procedure is often done after chemotherapy if residual masses remain or in early-stage cancer with a high risk of metastasis. RPLND requires expert surgical skill and may result in temporary digestive issues or loss of ejaculation due to nerve damage, though nerve-sparing techniques can help preserve function. It offers a potential cure when cancer is confined to the lymph nodes.5. Active SurveillanceActive surveillance is recommended for patients with early-stage testicular cancer, particularly those with low-risk seminomas or non-seminomas. This approach involves regular follow-ups, including physical exams, blood tests, and imaging, to monitor for recurrence without immediate treatment. It avoids overtreatment and preserves quality of life while maintaining high survival outcomes. If any signs of recurrence are detected, curative treatment is initiated promptly. This strategy is gaining popularity due to the excellent prognosis of testicular cancer and the desire to reduce long-term treatment-related side Epidemiology TrendsTesticular cancer continues to show distinctive epidemiological patterns that reflect both biological factors and evolving healthcare practices. While it remains a relatively rare form of cancer, accounting for a small percentage of male cancers globally, recent trends highlight significant developments in its incidence, demographics, risk patterns, and outcomes. These shifts are crucial for improving early detection strategies, tailoring public health initiatives, and optimizing treatment approaches.1. Rising Incidence in Developed RegionsOne of the most notable trends is the increasing incidence of testicular cancer in developed countries, particularly in Europe, North America, and Oceania. Although the underlying reasons are not fully understood, environmental and lifestyle factors, including exposure to endocrine-disrupting chemicals, delayed parenthood, and reduced physical activity, are believed to contribute. The increase is especially prominent among young and middle-aged men, which is prompting further investigation into genetic and environmental interactions. Improved diagnostic awareness and access to healthcare in these regions may also account for part of the rise.2. Age-Related Diagnosis PatternsTesticular cancer remains a disease that predominantly affects younger males, with the highest prevalence observed in individuals aged 15 to 40. However, recent years have shown subtle shifts in age-related diagnosis. While the median age remains consistent, there has been a gradual increase in cases among older men, particularly those over 55. This trend is drawing attention to the need for more inclusive awareness campaigns, which traditionally focus on younger populations. Age-specific changes in testicular function or prolonged exposure to risk factors might be contributing to these emerging patterns.3. Racial and Ethnic DisparitiesEpidemiological studies have shown that testicular cancer has higher incidence rates among Caucasian men compared to other racial or ethnic groups. However, recent data indicate a gradual narrowing of this gap, with incidence increasing among Hispanic and African American populations in some regions. This could reflect changes in environmental exposures or improvements in healthcare access and cancer reporting. These disparities underscore the importance of developing culturally relevant awareness and screening initiatives to ensure early diagnosis and effective treatment across all demographic groups.4. Improved Survival and Early DetectionSurvival rates for testicular cancer continue to improve, largely due to earlier detection and advances in treatment. Public awareness campaigns and the availability of high-quality diagnostic imaging have led to an increase in the detection of early-stage tumours. Consequently, more patients are receiving timely and effective interventions. The continued evolution of surgical techniques, chemotherapeutic regimens, and post-treatment surveillance strategies has significantly reduced mortality, especially in high-income nations. The focus now extends to survivorship care, including fertility preservation and management of long-term side effects.5. Increased Incidence of Germ Cell TumoursThere has been a documented rise in germ cell tumours, the most common histological subtype of testicular cancer. These tumours, which include both seminomas and non-seminomas, are believed to have origins in foetal development but typically manifest in adolescence or early adulthood. The increasing incidence suggests a complex interplay between genetic susceptibility and prenatal or early-life environmental factors. Research is ongoing to understand these triggers, and the trend reinforces the need for longitudinal studies and targeted preventive strategies focused on reproductive health and environmental risk By RegionThe epidemiology of testicular cancer varies across countries and regions due to differences in healthcare infrastructure, socioeconomic factors, cultural attitudes towards pain, and access to pain management therapies. Understanding these variations is essential for developing targeted interventions and improving patient regions include: The United States Germany France Italy Spain The United Kingdom Japan India These regions exhibit distinct epidemiological trends, reflecting the unique challenges and opportunities within their healthcare prevalence of testicular cancer differs notably across countries, influenced by genetic predispositions (including family history and conditions like cryptorchidism), lifestyle habits, dietary patterns, environmental influences, and disparities in healthcare access. In The United States, it is estimated that approximately 10,000 men are diagnosed with testicular cancer each Questions Answered What are the primary genetic and environmental risk factors associated with the incidence of testicular cancer across different populations? How does the age distribution of testicular cancer diagnoses vary across global regions? What trends have emerged over the past decade in testicular cancer incidence and mortality rates? How do racial and ethnic differences influence testicular cancer prevalence and survival outcomes? What role does early detection play in improving survival rates for testicular cancer patients? How has the prevalence of testicular cancer changed in high-income versus low-income countries? What is the impact of cryptorchidism on the lifetime risk of developing testicular cancer? How do lifestyle factors such as smoking, physical activity, or diet correlate with testicular cancer risk? What is the average latency period between exposure to risk factors and onset of testicular cancer symptoms? How accurate and complete are cancer registries in capturing the true burden of testicular cancer globally? Scope of the Report The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of testicular cancer based on several factors. The testicular cancer epidemiology forecast report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India) The report helps to identify the patient population, the unmet needs of testicular cancer are highlighted along with an assessment of the disease's risk and burden. Key Topics Covered1 Preface1.1 Introduction1.2 Objectives of the Study1.3 Research Methodology and Assumptions2 Executive Summary3 Testicular Cancer Market Overview - 8 MM3.1 Testicular Cancer Market Historical Value (2018-2024)3.2 Testicular Cancer Market Forecast Value (2025-2034)4 Testicular Cancer Epidemiology Overview - 8 MM4.1 Testicular Cancer Epidemiology Scenario (2018-2024)4.2 Testicular Cancer Epidemiology Forecast5 Disease Overview5.1 Signs and Symptoms5.2 Causes5.3 Risk Factors5.4 Guidelines and Stages5.5 Pathophysiology5.6 Screening and Diagnosis5.7 Types of Testicular Cancer6 Patient Profile6.1 Patient Profile Overview6.2 Patient Psychology and Emotional Impact Factors7 Epidemiology Scenario and Forecast - 8 MM7.1 Key Findings7.2 Assumptions and Rationale7.3 Testicular Cancer Epidemiology Scenario in 8MM (2018-2034)8 Epidemiology Scenario and Forecast: United States8.1 Testicular Cancer Epidemiology Scenario and Forecast in The United States (2018-2034)9 Epidemiology Scenario and Forecast: United Kingdom9.1 Testicular Cancer Epidemiology Scenario and Forecast in United Kingdom (2018-2034)10 Epidemiology Scenario and Forecast: Germany10.1 Testicular Cancer Epidemiology Scenario and Forecast in Germany (2018-2034)11 Epidemiology Scenario and Forecast: France11.1 Testicular Cancer Epidemiology Scenario and Forecast in France12 Epidemiology Scenario and Forecast: Italy12.1 Testicular Cancer Epidemiology Scenario and Forecast in Italy (2018-2034)13 Epidemiology Scenario and Forecast: Spain13.1 Testicular Cancer Epidemiology Scenario and Forecast in Spain (2018-2034)14 Epidemiology Scenario and Forecast: Japan14.1 Testicular Cancer Epidemiology Scenario and Forecast in Japan (2018-2034)15 Epidemiology Scenario and Forecast: India15.1 Testicular Cancer Epidemiology Scenario and Forecast in India (2018-2034)16 Patient Journey17 Treatment Challenges and Unmet Needs18 Key Opinion Leaders (KOL) InsightsFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store